vs
EDGEWELL PERSONAL CARE Co（EPC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是EDGEWELL PERSONAL CARE Co的1.8倍（$772.1M vs $422.8M），Revvity净利率更高（12.7% vs -15.5%，领先28.3%），Revvity同比增速更快（5.9% vs -11.6%），Revvity自由现金流更多（$161.8M vs $-137.5M），过去两年Revvity的营收复合增速更高（9.0% vs -16.0%）
Edgewell个人护理是一家总部位于美国康涅狄格州谢尔顿的跨国消费品企业，主营业务聚焦个人护理产品领域。公司在2015年从劲量控股分拆后正式成立，目前在全球多个市场开展个人护理相关业务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EPC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$422.8M
营收增速更快
RVTY
高出17.5%
-11.6%
净利率更高
RVTY
高出28.3%
-15.5%
自由现金流更多
RVTY
多$299.3M
$-137.5M
两年增速更快
RVTY
近两年复合增速
-16.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $422.8M | $772.1M |
| 净利润 | $-65.7M | $98.4M |
| 毛利率 | 38.1% | — |
| 营业利润率 | -4.5% | 14.5% |
| 净利率 | -15.5% | 12.7% |
| 营收同比 | -11.6% | 5.9% |
| 净利润同比 | -3028.6% | 3.9% |
| 每股收益（稀释后） | $-1.41 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EPCRVTY
| Q4 25 | $422.8M | $772.1M | ||
| Q3 25 | $600.5M | $698.9M | ||
| Q2 25 | $627.2M | $720.3M | ||
| Q1 25 | $580.7M | $664.8M | ||
| Q4 24 | $415.1M | $729.4M | ||
| Q3 24 | $517.6M | $684.0M | ||
| Q2 24 | $647.8M | $691.7M | ||
| Q1 24 | $599.4M | $649.9M |
净利润EPCRVTY
| Q4 25 | $-65.7M | $98.4M | ||
| Q3 25 | $-30.6M | $46.7M | ||
| Q2 25 | $29.1M | $53.9M | ||
| Q1 25 | $29.0M | $42.2M | ||
| Q4 24 | $-2.1M | $94.6M | ||
| Q3 24 | $8.8M | $94.4M | ||
| Q2 24 | $49.0M | $55.4M | ||
| Q1 24 | $36.0M | $26.0M |
毛利率EPCRVTY
| Q4 25 | 38.1% | — | ||
| Q3 25 | 37.9% | 53.6% | ||
| Q2 25 | 42.8% | 54.5% | ||
| Q1 25 | 44.1% | 56.5% | ||
| Q4 24 | 41.6% | — | ||
| Q3 24 | 41.1% | 56.3% | ||
| Q2 24 | 44.3% | 55.7% | ||
| Q1 24 | 43.1% | 54.6% |
营业利润率EPCRVTY
| Q4 25 | -4.5% | 14.5% | ||
| Q3 25 | -4.2% | 11.7% | ||
| Q2 25 | 8.6% | 12.6% | ||
| Q1 25 | 10.1% | 10.9% | ||
| Q4 24 | 2.2% | 16.3% | ||
| Q3 24 | 3.9% | 14.3% | ||
| Q2 24 | 12.8% | 12.4% | ||
| Q1 24 | 11.7% | 6.8% |
净利率EPCRVTY
| Q4 25 | -15.5% | 12.7% | ||
| Q3 25 | -5.1% | 6.7% | ||
| Q2 25 | 4.6% | 7.5% | ||
| Q1 25 | 5.0% | 6.4% | ||
| Q4 24 | -0.5% | 13.0% | ||
| Q3 24 | 1.7% | 13.8% | ||
| Q2 24 | 7.6% | 8.0% | ||
| Q1 24 | 6.0% | 4.0% |
每股收益（稀释后）EPCRVTY
| Q4 25 | $-1.41 | $0.86 | ||
| Q3 25 | $-0.65 | $0.40 | ||
| Q2 25 | $0.62 | $0.46 | ||
| Q1 25 | $0.60 | $0.35 | ||
| Q4 24 | $-0.04 | $0.77 | ||
| Q3 24 | $0.18 | $0.77 | ||
| Q2 24 | $0.98 | $0.45 | ||
| Q1 24 | $0.72 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $1.5B | $7.3B |
| 总资产 | $3.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.03× | — |
8季度趋势，按日历期对齐
现金及短期投资EPCRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $209.1M | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务EPCRVTY
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.4B | — |
股东权益EPCRVTY
| Q4 25 | $1.5B | $7.3B | ||
| Q3 25 | $1.6B | $7.4B | ||
| Q2 25 | $1.6B | $7.6B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.5B | $7.7B | ||
| Q3 24 | $1.6B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
总资产EPCRVTY
| Q4 25 | $3.8B | $12.2B | ||
| Q3 25 | $3.8B | $12.1B | ||
| Q2 25 | $3.8B | $12.4B | ||
| Q1 25 | $3.8B | $12.4B | ||
| Q4 24 | $3.7B | $12.4B | ||
| Q3 24 | $3.7B | $12.8B | ||
| Q2 24 | $3.7B | $13.4B | ||
| Q1 24 | $3.8B | $13.4B |
负债/权益比EPCRVTY
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.89× | — | ||
| Q2 25 | 0.88× | — | ||
| Q1 25 | 0.95× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 0.81× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-125.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-137.5M | $161.8M |
| 自由现金流率自由现金流/营收 | -32.5% | 21.0% |
| 资本支出强度资本支出/营收 | 2.7% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $36.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流EPCRVTY
| Q4 25 | $-125.9M | $182.0M | ||
| Q3 25 | $74.1M | $138.5M | ||
| Q2 25 | $114.8M | $134.3M | ||
| Q1 25 | $45.1M | $128.2M | ||
| Q4 24 | $-115.6M | $174.2M | ||
| Q3 24 | $-388.3M | $147.9M | ||
| Q2 24 | $101.2M | $158.6M | ||
| Q1 24 | $129.0M | $147.6M |
自由现金流EPCRVTY
| Q4 25 | $-137.5M | $161.8M | ||
| Q3 25 | $46.5M | $120.0M | ||
| Q2 25 | $99.3M | $115.5M | ||
| Q1 25 | $28.0M | $112.2M | ||
| Q4 24 | $-132.4M | $149.8M | ||
| Q3 24 | $-414.2M | $125.6M | ||
| Q2 24 | $88.6M | $136.6M | ||
| Q1 24 | $117.5M | $129.7M |
自由现金流率EPCRVTY
| Q4 25 | -32.5% | 21.0% | ||
| Q3 25 | 7.7% | 17.2% | ||
| Q2 25 | 15.8% | 16.0% | ||
| Q1 25 | 4.8% | 16.9% | ||
| Q4 24 | -31.9% | 20.5% | ||
| Q3 24 | -80.0% | 18.4% | ||
| Q2 24 | 13.7% | 19.7% | ||
| Q1 24 | 19.6% | 20.0% |
资本支出强度EPCRVTY
| Q4 25 | 2.7% | 2.6% | ||
| Q3 25 | 4.6% | 2.6% | ||
| Q2 25 | 2.5% | 2.6% | ||
| Q1 25 | 2.9% | 2.4% | ||
| Q4 24 | 4.0% | 3.4% | ||
| Q3 24 | 5.0% | 3.3% | ||
| Q2 24 | 1.9% | 3.2% | ||
| Q1 24 | 1.9% | 2.7% |
现金转化率EPCRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 3.95× | 2.49× | ||
| Q1 25 | 1.56× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | -44.13× | 1.57× | ||
| Q2 24 | 2.07× | 2.87× | ||
| Q1 24 | 3.58× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPC
| Other | $242.0M | 57% |
| Sunand Skin Care Segment | $131.5M | 31% |
| Shavinggelsandcreams | $32.3M | 8% |
| Wipes And Other Skin Care Products | $17.0M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
